|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 May 2004, Vol. 103, No. 10, pp. 3821-3827. Prepublished online as a Blood First Edition Paper on January 15, 2004; DOI 10.1182/blood-2003-09-3359.
IMMUNOBIOLOGY SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative diseaseFrom the Molecular Immunology Unit, Institute of Child Health, University College London, London, United Kingdom; the Department of Clinical Immunology, Great Ormond Street Hospital National Health Service (NHS) Trust, London, United Kingdom; and the Academic Unit of Child Health, University of Manchester, St Mary's Hospital, Manchester, United Kingdom.
Cytotoxic T cells (CTLs) and natural killer cells play a major role in the immune response to Epstein-Barr virus (EBV) infection. In X-linked lymphoproliferative (XLP) disease, a severe immunodeficiency, immunodysregulatory phenomena are observed following EBV infection, suggesting that defects exist in these effector populations. The gene defective in XLP is SAP (signaling lymphocytic activation molecule [SLAM]–associated protein), an adaptor protein that mediates signals through SLAM and other immunoglobulin superfamily receptors including 2B4. We generated EBV-specific T-cell lines from controls and XLP patients and examined CTL function in response to different stimuli. We show that XLP patients can generate EBV–T-cell lines that are phenotypically similar to those from controls. XLP patient EBV–T-cell lines showed a significant decrease in interferon-gamma (IFN-  ) production in response to 2B4 and autologous EBV-transformed lymphoblastoid cell line (LCL) stimulation but not in response to SLAM. Furthermore, XLP EBV–T-cell lines demonstrated markedly decreased cytotoxic activity against autologous LCLs. By retroviral gene transfer of the SAP gene into XLP EBV–T-cell lines, we show reconstitution of IFN- production and of cytotoxic activity confirming SAP-dependent defects. These studies demonstrate that in XLP the lack of SAP affects specific signaling pathways resulting in severe disruption of CTL function.
X-linked lymphoproliferative disease (XLP), or Duncan disease, is an inherited syndrome characterized by immunedysregulatory phenomena typically following Epstein-Barr virus (EBV) infection that leads to severe infectious mononucleosis, acquired hypogammaglobulinemia, and/or malignant lymphoma.1 The defective gene in XLP has been identified as src homology 2 domain protein 1A (SH2D1A),2 also known as signaling lymphocytic activation molecule (SLAM)–associated protein (SAP) gene.3 SAP is thought to be involved in the coordination of the immune response to EBV or other viral infections. SAP is expressed in natural killer (NK), CD4+, and CD8+ T cells3-5 but not in monocytes6 and primary B cells, although expression in certain B-cell lines has been documented.7
The ligand for SAP was initially defined as SLAM (CD150), a member of the immunoglobulin (Ig) superfamily and a costimulatory molecule found on the surface of T and B lymphocytes and dendritic cells.8 SLAM is a self-ligand and has a number of diverse functions including T/B-lymphocyte costimulation,9 regulation of T-cell cytotoxicity,10 and induction of interferon-
In most cases of XLP, EBV plays a critical role as a trigger of pathologic phenotypes. EBV is a human
Studies on specific T-cell immunity to EBV in XLP are contradictory. EBV-specific memory T-cell activity as measured by inhibition of autologous LCL outgrowth (regression assay) was defective in the majority of XLP patients studied by Harada et al,19 but other studies claim normal EBV-specific HLA-restricted cytotoxic activity,20 although no specific blocking experiments were undertaken. The production of IFN-
To understand the cellular defects in XLP we developed an autologous EBV-LCL/EBV–T-cell line model from XLP patients and studied the phenotypic profile and functionality of effector T cells. We show that in response to specific stimuli, the IFN-
Generation of SAP-expressing retroviral vector Human SAP(SH2D1A) cDNA (Online Mendelian Inheritance in Man [OMIM] no., AL023657 [GenBank] ) cloned into pGEM-T (Promega, Madison, WI) was a gift from Dr Alison Coffey (The Sanger Center, Cambridge, United Kingdom). SAP cDNA was amplified using the following primers. The forward primer, SAP-F, containing a SalI restriction site (underlined), was placed upstream of the initiation codon and the reverse primer, SAP-R, downstream at codon 553 but upstream of the polyA+ signal. The primers used are as follows: SAP-F, GCC CAA GAG TCG ACC AGG CCA TGG; SAP-R, GTA CAA GGT GTT TTA GTC GAC TTC ATG GGG GCT TTC. The 400–base pair (bp) product was digested with SalI and cloned into plasmid Blue script (pBS; Promega), sequenced, and then subcloned into the retroviral backbone. A murine replication-deficient oncoretroviral vector containing the U3 modified 3' long terminal repeat (LTR) from spleen focus-forming virus (SFFV), 5'LTR from PCMV (PCC4 cell passaged murine sarcoma virus),26 and primer binding site (pbs)27 was used for enhanced hematopoietic cell tropism and reduced transgene silencing. Human SAP cDNA was cloned upstream of the encephalomyocarditis virus–derived internal ribosomal entry sequence (IRES) sequence and red-shifted variant of the enhanced green fluorescent protein (eGFP). Vectors containing only eGFP were generated for controls in all experiments. The PG13 packaging cell line (providing the Gibbon ape leukemia virus envelope protein) was used to generate replication-defective virus. One clone producing virus at 107 transducing units/mL was selected. Purification of PBMCs from healthy and XLP patients This study was approved by the institutional research ethics committee and informed consent was obtained from all subjects before taking blood. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density centrifugation from anticoagulated whole blood derived from 3 healthy donors (C) and 3 XLP patients (P1, P2, and P3). The 3 patients were all from different kindreds and each had a different mutation in the SAP gene, which led to the absence of SAP expression.6 The clinical phenotype of each patient was different: P1 was EBV seropositive and previous fulminant IM, P2 was EBV seropositive and previous B-cell lymphoma treated with chemotherapy, and P3 was EBV seronegative and had dysgammaglobulinemia. Generation and culture of EBV–T-cell lines EBV-transformed LCLs were generated from healthy donors and EBV-seropositive XLP patients (P1 and P2) using standard techniques. EBV–T-cell lines were generated by stimulating 1 x 106/mL PBMCs cells with 2.5 x 104/mL autologous LCLs (40:1 cell ratio) using standard culture conditions.28 Cells were washed, recultured at a concentration of 1 x 106/mL, and restimulated with 2 x 105/mL autologous LCLs at day 9. Cells were either prepared for gene transfer on day 10 or kept in culture with restimulations weekly at an effector-target ratio of 4:1. A total of 20 IU IL-2 (Proleukin; Chiron, Emeryville, CA) was added to the cultures for the first time at day 10 and twice weekly thereafter. All cell lines were cultured up to 8 to 10 weeks. EBV–T-cell lines with mainly a CD4+ phenotype were produced by stimulation with phytohemagglutinin (PHA, 5 ng/mL) and IL-2 (20 IU/mL) at day 7 and continued in the same conditions as described above for generation of CD8+ EBV–T-cell lines. The data for enzyme-linked immunospot (ELISPOT) and cytotoxicity experiments are from studies on CD8+ EBV–T-cell lines. Gene transfer EBV–T-cell lines (days 9-10) were placed in retronectin-coated wells loaded with virus supernatant. Retronectin (Takara Biomedicals, Shiga, Japan) at 18.5 µg/mL was coated on non–tissue culture–treated plates for 2 hours at 37° C in 24-well plates. Plates were blocked with 1% human serum albumin for 60 minutes and washed twice with PBS. Cells were plated at a concentration of 1 x 106/mL for 24 hours. Half of the supernatant was replaced with fresh medium containing 10% heat-inactivated fetal calf serum (FCS) and 20 IU/mL IL-2. A second round of virus exposure was performed after 24 hours in the same conditions. Cells were maintained in culture at a concentration of 1 x 106/mL to 1.5 x 106/mL. Cells were analyzed 3 days later by flow cytometry for expression of the reporter gene eGFP. Cell lines were sorted after 4 weeks of stimulation to reach maximum transduced cell purity. LDH release cytotoxic assay Cytotoxicity of EBV–T-cell lines was measured using lactate dehydrogenase (LDH) release assays (Promega). Briefly, autologous LCLs were used as target cells with EBV–T-cell lines as effector cells at different effector-target cell ratios. All targets were plated in triplicate. After a 4-hour incubation, supernatants were harvested and the specific cytotoxicity was determined using a microplate enzyme-linked immunosorbent assay reader (Dynatech Labs, Chantilly, VA). The percentage of specific lysis was calculated as 100% x (experimental release–spontaneous release)/(maximum release–spontaneous release). Maximum release was obtained by adding 100 µL of 5% Triton X-100 to the 100 µL medium containing target cells. Spontaneous release was consistently less than 15% of maximum release in all assays. ELISPOT assay
The ELISPOT assay was performed as described29 with some modifications. PBMCs and EBV–T-cell lines were plated at 1 x 104/well. Responder cell populations were seeded across a range of concentrations to achieve 10 to 100 spots/well so as to facilitate accurate and reproducible counting. For LCL stimulators with PBMC responders, the concentration used was 5 x 103 LCLs to 2 x 104 PBMC/well; for stimulators with EBV–T-cell line responders, this was 5 x 103 LCLs to 2 x 104 EBV–T-cell lines/well. For antibody stimulation of PBMCs and EBV–T-cell lines, all antibody concentrations used in the ELISPOT assay were optimized at 5 µg/mL: CD3 (OKT3; Janssen-Cilag, High Wycombe, United Kingdom), CD28 (BD Pharmingen, San Diego, CA), Statistical analysis Control values for each experiment (Figures 2,4) were derived from pooled data on a number of control individuals so that each experiment has a single control value, mean, and standard deviation. For experiments in Figure 2, 3 different control individuals were studied each in triplicate, and therefore the control mean is obtained from 9 data points. For experiments in Figure 4, 2 different control individuals were studied each in triplicate, and therefore the control mean is obtained from 6 data points. Each mean patient response and variance was then compared against the control response for each experiment and analyzed for statistical significance using a one-tail unpaired t test, assuming unequal variance between the 2 study groups. Significant differences are indicated by asterisks (no asterisk, no statistical significance; *P < .05; **P < .01; ***P < .001).
SAP immunoblotting Cell lysates were prepared from SAP-reconstituted and nonreconstituted EBV–T-cell lines from patients and healthy donors, according to previous protocols. The lysates (1 x 106 cells) were fractionated on sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels and analyzed by blotting onto nitrocellulose (MSI, Bedford, MA), blocking with 2.5% milk in PBS/0.1% Tw, and immunoblotting with anti-SAP antibody generated against the C-terminal end of SAP protein7 at a final concentration of 1:1000. The membrane was washed with PBS/0.1% Tw and incubated with a horseradish peroxidase–conjugated antirabbit antibody (Sigma) and washed again before enhanced chemiluminescence (ECL; Amersham Biosciences, Amersham, United Kingdom) detection. Flow cytometric analysis and FACS
Flow cytometry of EBV–T-cell lines was performed using an EPICS XL flow cytometer (Beckman Coulter) and antibodies for CD3, CD4, CD8, CD16, CD25, CD27, CD28, CD45RA, CD45RO, CD56, CD69, CD95 (Fas), CDw150 (SLAM), CD244 (2B4), T-cell receptor Gene-modified EBV–T-cell lines were purified using an EPICS Altra fluorescence activated cell sorter (FACS) (Beckman Coulter). Cells were stained with phycoerythrin (PE)–conjugated CD3 (BD Pharmingen) and analyzed for PE-CD3 and eGFP expression. Dual-color positive cells (positive fraction) and single-color CD3 cells (negative fraction) were sorted to high purity (more than 99%). One unsorted fraction was retained. The 3 cell fractions were subsequently used separately for cytotoxicity assays. MHC class I blocking of target cells W6/32 monoclonal antibody (mAb; a gift from Dr Bin Gao, ICH, London, United Kingdom) was used to block major histocompatibility complex (MHC) class I antigen presentation on LCLs. Cells were washed twice with PBS and then incubated with W6/32 mAb (1 µg/mL) on ice for one hour. The cells were then washed and used in cytotoxicity assays.
Immunophenotypic characteristics of EBV–T-cell lines from XLP patients The cellular response to EBV infection is mediated predominantly by CD8+ cytotoxic T cells, which retain memory and provide lifelong immunity against EBV. The detailed immunophenotype and function of EBV–T-cell lines derived from XLP patients has not previously been reported. Using autologous LCLs as stimulators, EBV–T-cell lines from 2 healthy individuals (CTLC1 and CTLC2) and 2 XLP patients (CTLP1 and CTLP2) were generated. Detailed cell surface analysis of CD8+ and CD4+ EBV–T-cell lines generated from both XLP patients and healthy individuals revealed similar surface marker expression profiles (Table 1). Expression of memory/naive (CD45RO/CD45RA) and activation (CD25 and CD69) markers was similar in cell lines derived from healthy and XLP individuals with comparable mean fluorescence intensity (MFI) for the majority of markers studied.
Previous reports have suggested that SLAM is the dominant molecule mediating cytotoxicity in T lymphocytes. However, in this analysis we found very low surface expression of SLAM on EBV–T-cell lines from both healthy and XLP individuals, while in contrast 2B4 is highly expressed on these cell lines (Figure 1; Table 1), suggesting that 2B4 rather than SLAM may be more important in mediating cytotoxicity in EBV–T-cell lines.
IFN-
IFN- EBV–T-cell line function in XLP and reconstitution of defects following SAP gene transfer It has been postulated that the cellular pathogenesis of XLP may reside in abnormal function of EBV–T-cell lines and in their inability to control EBV infection. Previous reports, performed before the identification of the SAP gene defect, are inconclusive with certain studies demonstrating that cytokine secretion and cytotoxicity are abnormal and others suggesting that both functions are intact. We examined whether introducing expression of the SAP gene into EBV–T-cell lines from XLP patients (known to lack SAP expression) could restore these observed functional defects. We transduced EBV–T-cell lines from XLP patients P1 and P2 (CTLP1 and CTLP2) with a retroviral vector encoding the SAP cDNA and the reporter eGFP (SAP-transduced cells designated S + CTLP1 and S + CTLP2). Transduced EBV–T-cell lines were analyzed and showed the same phenotypic characteristics as the parent cell lines (data not shown). The expression of eGFP and SAP in the transduced cell lines was confirmed by flow cytometric and immunoblot analysis, respectively (Figure 3A-B). The percentage of cells transduced was approximately 45%, and these cells were purified by FACS for use in the reconstitution experiments described in Figures 4 and 5.
CD8+ EBV–T-cell lines from healthy individuals (C), XLP patients untransduced (CTLP1, CTLP2), and SAP transduced (S + CTLP1, S + CTLP2) were then activated with the same set of stimuli used in the PBMC experiments described in Figure 2. Following PMA, CD3, CD28, CD3/CD28, SLAM, and CD3/ SLAM stimulation no difference in IFN- We next tested the ability of XLP EBV–T-cell lines to kill autologous LCLs using a standard LDH release assay (Figure 5). EBV–T-cell lines from both XLP patient P1 and P2 showed markedly decreased cytotoxic activity in comparison with EBV–T-cell lines from 2 healthy individuals (Figure 5A-D). SAP reconstitution experiments were then performed to see if cytotoxic function could be restored to XLP EBV–T-cell lines. We demonstrate that cytotoxic function can be increased from 30% to 60% cell lysis for CTLP1 (Figure 5C), and from 20% to 60% for CTLP2 (Figure 5D), at effector-target cell ratios of 10:1. At similar effector-target cell ratios, approximately 80% cell lysis was seen in EBV–T-cell lines from healthy individuals C1 and C2 (Figure 5A-B). Normal EBV–T-cell lines transduced with SAP or eGFP (S + CTL or G + CTL) or XLP EBV–T-cell lines transduced with eGFP (G + CTLP) did not show any differences in cytotoxic activity from untransduced cell lines, again suggesting that retroviral transduction per se did not affect cytotoxic activity. To confirm MHC class I–specific mediated killing, incubation with an MHC class I antibody reduced cytotoxic activity to 20% to 30% cell lysis in both normal and S + CTLP lines (Figure 5E).
Following the identification of SAP as the defective gene in XLP, there has been considerable progress in the understanding of the SAP protein structure, its interaction with cell surface molecules and more recently with proximal tyrosine kinases such as FynT.15,16 However, the cellular pathogenesis of XLP in humans remains poorly understood, especially given the different clinical phenotypes of the disease. Murine models of SAP deficiency suggest a tendency to dysregulated Th1 responses with T-cell activation and increased IFN- production, but it is clear from studies of other immunodeficiencies that abnormalities observed in murine models do not always accurately reflect human disease.30 It is evident from a number of reports that human NK cell defects are present in this condition,17,18,31 but there are very little clear functional data on specific T-cell populations. In this study the use of EBV–T-cell lines from XLP patients represents a physiologic human T-cell effector population. The lack of cellular transformation or species differences provides a relevant model for examining defects in this condition. In healthy individuals the immune response to EBV infection, the major pathologic trigger in XLP, is dominated by the proliferation of CD8+ EBV–T-cell lines and NK cells. The development of EBV-driven lymphoma and fulminant IM in XLP32 would strongly suggest that defects exist in these effector populations. In this study we show that XLP patients are indeed capable of generating EBV–T-cell lines. Using different culture conditions we were able to generate T-cell lines of both CD8+ and CD4+ phenotype from both healthy and XLP patients. Although most cytotoxic T-cell lines are CD8+, polyclonal expansion of T cells in response to viral antigens33 can result in CD4+ T-cell lines and CD4+ cytotoxicity is well documented.34 Cell surface marker expression profiles and intensity of expression were similar in both XLP and control groups. In both controls and XLP EBV–T-cell lines there was very little SLAM expression observed, while 2B4 was expressed at significant levels. To date, SLAM has been cited as the main partner for SAP binding and as an important costimulatory molecule in T-cell responses to antigenic stimulation. Much of this work has been performed on murine T cells and the differential expression of SLAM and 2B4 in human effector cells has not been extensively studied. Our analysis shows abundant 2B4 expression in both control and XLP EBV–T-cell lines, while SLAM expression was minimal. Furthermore, in preliminary studies, stimulation of EBV–T-cell lines and PBMCs from healthy individuals shows no significant enhancement in SLAM expression (R.S., H.B.G., unpublished data, 2004). Our observations would suggest that 2B4, not SLAM, is the major partner for SAP in EBV–T-cell lines and, as previously observed in NK cells, signaling through 2B4 in XLP EBV–T-cell lines may be defective.
A number of studies have reported cytokine abnormalities in XLP. However, in the majority of studies undertaken, the response to specific cell surface stimuli has not been addressed. In this analysis we stimulated both PBMCs and XLP EBV–T-cell lines with specific T-cell stimuli and assessed the IFN-
Following CD3 stimulation alone, P1 and P2, who are EBV experienced, demonstrate significant down-regulation of IFN-
In our study, differences in XLP and normal EBV–T-cell lines following CD3/2B4 or 2B4 activation suggest that activation through this specific pathway is important in EBV–T-cell line function and, given the similarities in the cell surface phenotype between the 2 T-cell populations, point to defective SAP expression as being responsible for aberrant transduction of the 2B4 signal. Similar findings after stimulation by autologous LCLs are consistent with these findings. Cell surface LCL/EBV–T-cell line interactions include homotypic association between SLAM molecules (although in this study low SLAM expression negates this pathway) and also between 2B4 on EBV–T-cell lines with its ligand CD48, which is abundantly expressed on LCLs. Disruption of the signal arising from this interaction results from the lack of SAP expression in XLP EBV–T-cell lines probably leading to decreased IFN-
Our studies on human cells from EBV-experienced individuals demonstrate a decrease in IFN- We demonstrate that human EBV–T-cell lines from 2 patients with a molecular diagnosis of XLP and lack of SAP expression show significant defects in direct killing of autologous LCLs. Previous studies have suggested this using indirect assays such as LCL growth regression. That this defect occurs via the 2B4/CD48 pathway is supported by the abundance of 2B4 rather than SLAM expression and also by the demonstration of 2B4/CD48 abnormalities in NK cell cytotoxicity in XLP.18 The molecular detail of this pathway is unclear, but it has been shown that 2B4 associates with the LAT (linker for activation of T cells) leading to tyrosine phosphorylation of both molecules. Whether this interaction is SAP dependent has yet to be defined. It is also evident that other receptors are involved in mediating cytotoxicity in T cells. NTB-A is a recently identified member of the SLAM family and can bind SAP following phosphorylation of its cytoplasmic tail.36 NTB-A behaves in an analogous manner to 2B4 in NK cells triggering cytotoxicity but is also expressed in T cells suggesting that the observed defects in XLP EBV–T-cell lines may arise from abnormal signaling downstream of a number of different surface receptors. The final events in these pathways may be the inability to form the cytolytic machinery such as release of granzyme or perforin molecules, and expression of such proteins in XLP EBV–T-cell lines is currently being investigated. The cytokine expression and cytotoxicity defects are SAP dependent since introduction of SAP by gene transfer restored functionality. A marked increase was seen in both patients for cytotoxicity and cytokine assays. The restoration of function was equivalent to control samples and mock-transfected cells did not show any reconstitution. Retroviral transfer of the SAP gene into EBV–T-cell lines was achieved during the repeated stimulation of T cells by autologous LCLs and makes CTLs an attractive target for gene transfer. Although the studies were principally conducted to show that the defects were SAP dependent, the restoration of function suggests that SAP gene transfer in XLP may hold some therapeutic value. In cases without a matched sibling donor, gene-corrected CTLs could be generated and stored for future use if lymphoma or fulminant IM were to arise in XLP patients. However, much further work would be necessary to show that constitutive SAP expression under the control of a viral LTR does not lead to adverse effects. The possibility of SAP expression under the control of a T-lineage–restricted or endogenous SAP promoter could also be explored. To date, functional cytotoxic T-cell defects in XLP have not been carefully defined, especially in response to EBV infection. Using this autologous EBV-LCL/EBV–T-cell line model we clearly demonstrate that both cytokine production and cytolytic activity are severely impaired as a result of SAP deficiency. In combination with previously described NK cell defects this may explain the failure to control EBV infection and predisposition to B-cell lymphoma, which occurs in one third of XLP patients and that indeed was the presenting feature of XLP patient P2. One may also speculate that the tendency to fulminant IM (as in P1) and hemophagocytosis may possibly arise from the initial CTL and NK cell failure leading to further dysregulated immune responses.
This manuscript is dedicated to the memory of Jonathon May and his family for their invaluable help in the undertaking of this study. We are grateful to Ross Gilmour for help with statistical analysis.
Submitted September 30, 2003; accepted December 26, 2003.
Prepublished online as Blood First Edition Paper, January 15, 2004; DOI 10.1182/blood-2003-09-3359.
Supported by the Primary Immunodeficiency Association, and the University College London (R.S.). A.J.T. is supported by the Wellcome Trust.
An Inside Blood analysis of this article appears in the front of this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: H. Bobby Gaspar, Molecular Immunology Unit, Institute of Child Health, University College London, 30, Guilford St, London WC1N 1EH, United Kingdom; e-mail: h.gaspar{at}ich.ucl.ac.uk.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-SLAM (A12 clone; BD Pharmingen), 2B4 (C1.7 clone; Beckman Coulter, High Wycombe, United Kingdom), and as a positive control PBMCs or EBV–T-cell lines stimulated with 2.5 µg/mL phorbol myristate acetate (PMA; Sigma, St Louis, MO) and 1 µg/mL ionomycin (Sigma). All cells were cultured in RPMI-FCS 10% supplemented to a final volume of 200 µL/well. After undisturbed incubation for 24 to 48 hours at 37° C, with 5% CO2, plates were washed 4 times with PBS containing 0.05% Tween 20 (PBS/0.05% Tw). Wells were incubated with biotinylated "detection" antibody against IFN-
(TCR
(all from BD Pharmingen). 
